C Diff Drug Development

Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-pate …

Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …

Destiny Pharma has signed an exclusive collaboration and co-development agreement for the North American rights of NTCD-M3, its medicine to prevent...

A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23

Nature Reviews Microbiology - This Genome Watch explores how large-scale microbiome studies are facilitating discoveries in bacteriophage biology and functional capabilities that are prime for...

Bacterial vaccines fight against antimicrobial resistance

Learn about our ongoing C. diff treatment trial: a randomized, double-blind evaluation of CRS3123 vs. Oral Vancomycin for adults with C. difficile Infection.

This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults.

There's good news, and then there's excellent news. The good news is that Acurx Pharmaceuticals is nearing its Phase 3 trial to get a best-in-class front-line treatment for C. difficile to the... | February 21, 2023

Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.

Crystal structures of camelid heavy-chain antibody variable domains (VHHs) bound to fragments of the combined repetitive oligopeptides domain of Clostridiodes difficile toxin A (TcdA) reveal that the C-terminus of VHH A20 was located 30 Å away from the N-terminus of V …

SER-109, an investigational microbiome therapeutic for treating recurrent Clostridioides difficile infection, was well tolerated and showed clinical benefit.

Acurx Pharmaceuticals' (NASDAQ:ACXP) mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase 3

ClinicalTrials.gov identifier: NCT03183141.

Acurx Pharmaceuticals' mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase... | February 8, 2023

Dr. Jessica Allegretti discusses the recent abrupt ending of the CP101 clinical program and why options are important for patients with #Cdiff: https://t.co/zohpEkdELL pic.twitter.com/LHqctmfbA4— HCPLive (@MDMagazine) February 8, 2023

The worldwide Difficile Infections (Clostridium Difficile Associated Disease) Market is predicted to reach a valuation of US$ 809 Million in 2023, with a CAGR of 6% predicted from 2023 to 2033.Clostridium difficile infection (CDI) is a disease caused by toxic compounds produced by the spore-formi...

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth inte

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

The new report by Stratagem Market Insights titled Global Clostridium Difficile Infection Treatment Market Outlook Report 2022 2030 gives an in depth analysis of the global Clostridium Difficile Infection Treatment market assessing the market based on its segments like Type ...

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

.@VedantaBio is developing oral drugs that are designed to deliver defined bacterial consortia to treat diseases linked to the #microbiome including #CDiff & #IBD. A Phase 3 trial of Vedanta’s VE303 for the treatment of #rCdiff is planned to begin in 2023. https://t.co/Xyew5il3Ba— MTIG (@MTIG_News) January 31, 2023

Happy to share our work in @JAMANetworkOpen In our study patients treated with SER-109 (an oral microbiome therapeutic) had significantly greater improvements in disease-specific HRQOL scores compared with patients treated with placebo through 8 wks #cdiff https://t.co/zL1iUg3LBz pic.twitter.com/77wCrrTIlv— Abhishek Deshpande (@abhishek_dp) January 30, 2023